Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers, has announced its participation in the upcoming Stifel 2025 Virtual Targeted Oncology Forum. Dr. Lara S. Sullivan, who serves as President, CEO and Chief Medical Officer, will engage in a fireside chat on Wednesday, April 9, 2025, at 11:30 a.m. ET.
The company will also conduct one-on-one investor meetings during the event. Investors and interested parties can access both the live webcast and replay of the fireside chat through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website at ir.pyxisoncology.com.
Pyxis Oncology (Nasdaq: PYXS), un'azienda in fase clinica focalizzata sullo sviluppo di terapie di nuova generazione per i tumori difficili da trattare, ha annunciato la sua partecipazione al prossimo Stifel 2025 Virtual Targeted Oncology Forum. La Dott.ssa Lara S. Sullivan, che ricopre il ruolo di Presidente, CEO e Direttore Medico, parteciperà a una chiacchierata informale il mercoledì 9 aprile 2025, alle 11:30 a.m. ET.
L'azienda condurrà anche incontri individuali con gli investitori durante l'evento. Gli investitori e le parti interessate possono accedere sia alla diretta che alla registrazione della chiacchierata informale tramite la pagina Eventi e Presentazioni nella sezione Relazioni con gli Investitori del sito web di Pyxis Oncology all'indirizzo ir.pyxisoncology.com.
Pyxis Oncology (Nasdaq: PYXS), una empresa en etapa clínica centrada en el desarrollo de terapias de próxima generación para cánceres difíciles de tratar, ha anunciado su participación en el próximo Stifel 2025 Virtual Targeted Oncology Forum. La Dra. Lara S. Sullivan, quien se desempeña como Presidenta, CEO y Directora Médica, participará en una charla informal el miércoles 9 de abril de 2025, a las 11:30 a.m. ET.
La empresa también llevará a cabo reuniones individuales con inversores durante el evento. Los inversores y partes interesadas pueden acceder tanto a la transmisión en vivo como a la repetición de la charla informal a través de la página de Eventos y Presentaciones en la sección de Relaciones con Inversores del sitio web de Pyxis Oncology en ir.pyxisoncology.com.
Pyxis Oncology (Nasdaq: PYXS)는 치료하기 어려운 암을 위한 차세대 치료제를 개발하는 데 집중하는 임상 단계 회사로, 다가오는 Stifel 2025 Virtual Targeted Oncology Forum에 참여할 것이라고 발표했습니다. 라라 S. 설리반 박사(사장, CEO 및 최고 의료 책임자)는 2025년 4월 9일 수요일 오전 11시 30분 ET에 화상 대담에 참여할 예정입니다.
이 회사는 또한 행사 기간 동안 투자자와의 일대일 회의를 진행할 것입니다. 투자자와 관심 있는 분들은 Pyxis Oncology 웹사이트의 투자자 관계 섹션에 있는 이벤트 및 프레젠테이션 페이지를 통해 화상 대담의 실시간 웹캐스트와 재생을 모두 이용할 수 있습니다. ir.pyxisoncology.com에서 확인하세요.
Pyxis Oncology (Nasdaq: PYXS), une entreprise en phase clinique axée sur le développement de thérapies de nouvelle génération pour des cancers difficiles à traiter, a annoncé sa participation au prochain Stifel 2025 Virtual Targeted Oncology Forum. Dr. Lara S. Sullivan, qui occupe les fonctions de Présidente, PDG et Directrice Médicale, participera à une discussion informelle le mercredi 9 avril 2025, à 11h30 ET.
L'entreprise organisera également des réunions individuelles avec des investisseurs pendant l'événement. Les investisseurs et les parties intéressées peuvent accéder à la fois au webinaire en direct et à la rediffusion de la discussion informelle via la page Événements & Présentations dans la section Relations Investisseurs du site web de Pyxis Oncology à l'adresse ir.pyxisoncology.com.
Pyxis Oncology (Nasdaq: PYXS), ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapeutika der nächsten Generation für schwer behandelbare Krebserkrankungen konzentriert, hat seine Teilnahme am bevorstehenden Stifel 2025 Virtual Targeted Oncology Forum bekannt gegeben. Dr. Lara S. Sullivan, die als Präsidentin, CEO und Chief Medical Officer tätig ist, wird am Mittwoch, den 9. April 2025, um 11:30 Uhr ET an einem informellen Gespräch teilnehmen.
Das Unternehmen wird während der Veranstaltung auch persönliche Investorenmeetings durchführen. Investoren und Interessierte können sowohl auf den Live-Stream als auch auf die Wiederholung des informellen Gesprächs über die Seite Veranstaltungen & Präsentationen im Bereich Investor Relations der Pyxis Oncology-Website unter ir.pyxisoncology.com zugreifen.
- None.
- None.
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 11:30 a.m. ET. The Company will also be holding one-on-one investor meetings at the event.
A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential as differentiated mono and combination therapies. The lead product candidate, micvotabart pelidotin (“MICVO” formerly PYX-201), is an antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response.
To learn more, visit www.pyxisoncology.com or follow us on X (formerly known as Twitter) and LinkedIn.
Pyxis Oncology Contact
Pamela Connealy
CFO and COO
ir@pyxisoncology.com
FAQ
When is Pyxis Oncology (PYXS) presenting at the Stifel 2025 Virtual Targeted Oncology Forum?
How can investors watch Pyxis Oncology's (PYXS) presentation at the Stifel forum?
What type of meetings will Pyxis Oncology (PYXS) hold at the Stifel 2025 forum?
Who will represent Pyxis Oncology (PYXS) at the Stifel 2025 Virtual Targeted Oncology Forum?
